Alessandro Lo Giudice
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alessandro Lo Giudice has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Maria Vitale
Institute of Human Anatomy and Histology, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90133 Palermo, Italy
3 shared publications - Celeste Caruso Bavisotto
Institute of Human Anatomy and Histology, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90133 Palermo, Italy
3 shared publications - Giuseppa D'AMico
Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), University of Palermo, Palermo
3 shared publications - Martina Di Marco
Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy
3 shared publications - Claudia Campanella
Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy
2 shared publications - Francesca Chiara Cecala
Institute of Human Anatomy and Histology, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90133 Palermo, Italy
2 shared publications
Latest Publications
- Open Access
Understanding and Mimicking Glioblastoma Cells Migration Strategies Through Hydrogel-Based 3D Models
Glioblastoma (GBM) is one of the most aggressive primary brain tumors in adults, characterized by rapid growth, diffuse infiltration of surrounding brain parenchyma, and resistance to conventional therapies, resulting in poor prognosis. The diffuse infiltrative behavior of GBM represents a major therapeutic challenge, as cancer cells can disseminate beyond identifiable margins of the tumor, escaping complete eradication and contributing to recurrence. GBM cell migration is a heterogeneous process that can occur through distinct strategies, including single-cell and collective patterns, as well as through the formation of multicellular structures known as “oncostreams”. Understanding the mechanisms underlying these migratory modalities may help identify new targets for limiting local tumor dissemination and disease progression. In this context, a variety of in vitro models have been developed to investigate these processes. Among these, hydrogel-based scaffolds represent a promising platform to recapitulate some selected biochemical and biophysical properties of the brain extracellular matrix, enabling the investigation of how the extracellular environment cues influence GBM cell migration and invasion. In this review, we discuss the major cellular strategies of GBM cell migration and tissue invasion and critically examine hydrogel-based in vitro models used to investigate these processes, highlighting their design principles, biological relevance, and current limitations.
Open AccessUnderstanding and Mimicking Glioblastoma Cells Migration Strategies Through Hydrogel-Based 3D Models
Glioblastoma (GBM) is one of the most aggressive primary brain tumors in adults, characterized by rapid growth, diffuse infiltration of surrounding brain parenchyma, and resistance to conventional therapies, resulting in poor prognosis. The diffuse infiltrative behavior of GBM represents a major therapeutic challenge, as cancer cells can disseminate beyond identifiable margins of the tumor, escaping complete eradication and contributing to recurrence. GBM cell migration is a heterogeneous process that can occur through distinct strategies, including single-cell and collective patterns, as well as through the formation of multicellular structures known as “oncostreams”. Understanding the mechanisms underlying these migratory modalities may help identify new targets for limiting local tumor dissemination and disease progression. In this context, a variety of in vitro models have been developed to investigate these processes. Among these, hydrogel-based scaffolds represent a promising platform to recapitulate some selected biochemical and biophysical properties of the brain extracellular matrix, enabling the investigation of how the extracellular environment cues influence GBM cell migration and invasion. In this review, we discuss the major cellular strategies of GBM cell migration and tissue invasion and critically examine hydrogel-based in vitro models used to investigate these processes, highlighting their design principles, biological relevance, and current limitations.
- Open Access
- 3 April 2026
- Published by MDPI AG in Methods and Protocols
- Vol. 9 (2) , 61
Standardized Workflow for the Generation of Patient-Derived Glioblastoma Spheroids
Glioblastoma (GBM) is one of the most aggressive and therapy-resistant primary brain tumors, mainly due to its pronounced intratumoral heterogeneity and highly invasive phenotype. Patient-derived three-dimensional (3D) culture models, including tumor spheroids, represent valuable tools to preserve the cellular complexity, phenotypic plasticity, and microenvironmental features of GBM ex vivo. However, standardized and reproducible protocols for the generation and maintenance of GBM spheroids from surgical specimens are still limited. Here, we describe a detailed and robust protocol for the isolation, 3D cultures, and expansion of primary GBM cells obtained from patient biopsies, leading to the formation of stable and morphologically consistent spheroids. The protocol provides step-by-step instructions for tissue dissociation, cell seeding under low-adhesion conditions, optimization of culture density, and long-term spheroid maintenance. In addition, we include guidelines for the morpho-phenotypical characterization of the resulting 3D structures. This methodological workflow offers a reproducible platform for modeling GBM in vitro, enabling the study of tumor biology and supporting translational applications such as drug screening, biomarker validation, and patient-specific therapeutic testing in a 3D context.
- 3 April 2026
- Published by MDPI AG in Methods and Protocols
- Vol. 9 (2) , 61
Open AccessStandardized Workflow for the Generation of Patient-Derived Glioblastoma Spheroids
Glioblastoma (GBM) is one of the most aggressive and therapy-resistant primary brain tumors, mainly due to its pronounced intratumoral heterogeneity and highly invasive phenotype. Patient-derived three-dimensional (3D) culture models, including tumor spheroids, represent valuable tools to preserve the cellular complexity, phenotypic plasticity, and microenvironmental features of GBM ex vivo. However, standardized and reproducible protocols for the generation and maintenance of GBM spheroids from surgical specimens are still limited. Here, we describe a detailed and robust protocol for the isolation, 3D cultures, and expansion of primary GBM cells obtained from patient biopsies, leading to the formation of stable and morphologically consistent spheroids. The protocol provides step-by-step instructions for tissue dissociation, cell seeding under low-adhesion conditions, optimization of culture density, and long-term spheroid maintenance. In addition, we include guidelines for the morpho-phenotypical characterization of the resulting 3D structures. This methodological workflow offers a reproducible platform for modeling GBM in vitro, enabling the study of tumor biology and supporting translational applications such as drug screening, biomarker validation, and patient-specific therapeutic testing in a 3D context.
- Open Access
GSCs in the Transdifferentiation Phenomenon: Focus on CAR-T-Based Therapy
Glioblastoma (GBM) remains one of the most lethal brain tumors, largely due to the resilience and plasticity of glioblastoma stem cells (GSCs), which drive tumor growth, recurrence, and resistance to conventional therapies. A key mechanism underlying their aggressiveness is transdifferentiation, whereby GSCs acquire endothelial- and pericyte-like phenotypes, promoting neovascularization and remodeling the tumor microenvironment to sustain malignancy. Conventional treatments often fail to eliminate these resilient populations, highlighting the need for innovative targeted strategies. Chimeric antigen receptor (CAR)-based immunotherapies offer a targeted strategy to specifically eliminate GSCs and interfere with their role in promoting tumor vascularization and suppressing immune responses. This review aims to provide a comprehensive overview of the molecular mechanisms driving GSC transdifferentiation and to summarize the current landscape of CAR-T therapies developed to target these cells. By integrating knowledge of GSC biology with advances in CAR-T-based interventions, this work highlights the potential of next-generation immunotherapies to overcome therapeutic resistance, limit tumor recurrence, and improve clinical outcomes in GBM.
Open AccessGSCs in the Transdifferentiation Phenomenon: Focus on CAR-T-Based Therapy
Glioblastoma (GBM) remains one of the most lethal brain tumors, largely due to the resilience and plasticity of glioblastoma stem cells (GSCs), which drive tumor growth, recurrence, and resistance to conventional therapies. A key mechanism underlying their aggressiveness is transdifferentiation, whereby GSCs acquire endothelial- and pericyte-like phenotypes, promoting neovascularization and remodeling the tumor microenvironment to sustain malignancy. Conventional treatments often fail to eliminate these resilient populations, highlighting the need for innovative targeted strategies. Chimeric antigen receptor (CAR)-based immunotherapies offer a targeted strategy to specifically eliminate GSCs and interfere with their role in promoting tumor vascularization and suppressing immune responses. This review aims to provide a comprehensive overview of the molecular mechanisms driving GSC transdifferentiation and to summarize the current landscape of CAR-T therapies developed to target these cells. By integrating knowledge of GSC biology with advances in CAR-T-based interventions, this work highlights the potential of next-generation immunotherapies to overcome therapeutic resistance, limit tumor recurrence, and improve clinical outcomes in GBM.